Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A PRISMA-compliant meta-analysis

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Gao, Qijun ^a,b   Yang, Bo ^a   Guo, Yi ^c   Zheng, Feng ^d   Gilardi, Leonardo ^e  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Department of Pathology   (China)

^c WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF COLOGNE   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; PLACEBO; CARDIOTONIC AGENT; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BALLOON DILATATION; BLOOD CLOT LYSIS; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; HYPOTENSION; INCIDENCE; INTRACORONARY DRUG ADMINISTRATION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECTS; HEART STROKE VOLUME; MYOCARDIAL INFARCTION;

ADENOSINE; CARDIOTONIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84942434951     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001279     Document Type: Article

References (48)

1. st century: updated numbers and updated facts. JCvD. 2013; 1: 1-2.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13-20.
3. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72: 950-957.
4. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation. 1989; 80: 1388-1399.
5. Mukesh S, Tejaskumar S, Kavia K, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis. 2012; 6: 101-114.
6. Aung Naing K, Li L, Su Q, et al. Adenosine and verapamil for noreflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2013; 6: CD009503.
7. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: www.cochrane.org/resources/handbook/. (accessed 15.11.14).
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
9. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J. 2004; 68: 928-932.
10. Hendler A, Aronovich A, Kaluski E, et al. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIM. J Invasive Cardiol. 2006; 18: 32-36.
11. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007; 85: 476-482.
12. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv. 2000; 51: 27-31.
13. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the Attenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003; 59: 1-9.
14. Kim SJ, Kim W, Woo JS, et al. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol. 2012; 158: 88-92.
15. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010; 55: 2825-2832.
16. Tian F, Chen YD, Lü SZ, et al. Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction. Chin Med J (Engl). 2008; 121: 195-199.
17. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006; 92: 1278-1284.
18. Tsao TP, Cheng SM, Cheng CC, et al. Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy. Acta Cardiol. 2009; 64: 225-230.
19. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2011; 107: 1131-1135.
20. Sardella G, Lucisano L, Mancone M, et al. Effect of adenosine intracoronary bolus on myonecrosis occurrence in elective PCI (RACE trial). Int J Cardiol. 2012; 155: 456-459.
21. Sanati HR, Ghanavati R, Zahedmehr A, et al. Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial. J Tehran Univ Heart Center. 2013; 8: 28-34.
22. De Luca G, Iorio S, Venegoni L, et al. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS trial). Am J Cardiol. 2012; 109: 202-207.
23. Niccoli G, Falcioni E, Cosentino N, et al. Impact of accuracy of fractional flow reserve to reduction of microvascular resistance after intracoronary adenosine in patients with angina pectoris or non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014; 113: 1461-1467.
24. Li Y-B, Tong Z-C, Li Q, et al. Evaluation of short- and long-term efficacy of combined intracoronary administration of high-dose adenosine and tirofiban during primary PCI. Exp Clin Cardiol. 2014; 7: 1769-1780.
25. Niccoli G, Cristina S, Filippo C. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial. J Am Coll Cardiol. 2014; 63: 1454-1455.
26. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004; 94: 9-13.
27. Ji ZG, Han JM, Liu G, et al. Effect of adenosine on ischemia-reperfusion injury during percutaneous coronary intervention. J Clin Rehabilitative Tissue Eng Res. 2007; 11: 10399-10403.
28. Garcia-Dorado D, García-Del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014; 177: 935-941.
29. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitro-prusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013; 6: 580-589.
30. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011; 32: 867-877.
31. Fokkema ML, Vlaar PJ, Vogelzang M, et al. Effect of high dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009; 2: 323-329.
32. Micari A, Belcik TA, Balcells EA, et al. Improvement in micro-vascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005; 96: 1410-1415.
33. Akturk IF, Yalcin AA, Biyik I, et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of no-reflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014; 62: 389-397.
34. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101: 2154-2159.
35. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005; 150: 1015.
36. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008; 71: 283-289.
37. Tong ZC, Li Q, Chen M, et al. Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2013; 41: 839-844.
38. Grygier M, Araszkiewicz A, Lesiak M, et al. Effect of new method of intracoronary adenosine injection during primary percutaneous coronary intervention on microvascular reperfusion injury - clinical outcome and 1-year follow-up. Cardiology. 2013; 124: 199-206.
39. Darahim K, Mahdy MM, Ryan MM, et al. Does high-dose intracoronary adenosine improve regional systolic left ventricular function in patients with acute myocardial infarction? Egypt Heart J. 2014; 66: 289-297.
40. Wang J, Chen YD, Zhi G, et al. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol. 2012; 39: 247-252.
41. Zhang H, Tian N-L, Hu Z-Y, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J. 2012; 125: 1713-1719.
42. Grygier M, Araszkiewicz A, Lesiak M, et al. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data. Kardiol Pol. 2013; 71: 115-120.
43. Ernens I, Bousquenaud M, Lenoir B, et al. Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. J Leukoc Biol. 2015; 97: 9-18.
44. Charan Reddy KV. Regulatory noncoding RNAs in cardiovascular disease: shedding light on "dark matter". JCvD. 2014; 2: 360-369.
45. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015; 213: 60-83.
46. Ferrari D, Vitiello L, Idzko M, et al. Purinergic signaling in atherosclerosis. Trends Mol Med. 2015; 21: 184-192.
47. Forman MB, Stone W, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev. 2006; 24: 116-147.
48. Polimeni A, De Rosa S, Sorrentino S, et al. Intracoronary adenosine administration reduces MACE and heart failure in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of RCTs. Giornale Italiano di Cardiologia. 2014; 15(Suppl 1): e27.